DiabetesBe a Leader in Research and Practice

Explore all the ways we support research and practice - including the recently published Hypoglycemia Blueprint, the Diabetes Technology Practice Guideline, and research on reducing cardiovascular disease in diabetes.

Researchers reveal link between PCOS, type 2 diabetes
August 29, 2017 | Women who have polycystic ovary syndrome (PCOS) have a higher risk of developing type 2 diabetes (T2D) and are diagnosed at an earlier age with the condition, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism

Childhood Obesity Quadruples Risk of Developing Type 2 Diabetes
June 2017 | Obese children have a fourfold greater risk of developing type 2 diabetes compared to normal-weight counterparts, according to a study published in the Journal of the Endocrine Society.…

Researchers Recommend Specific Diabetes Medications to Protect Bone Health
June 21, 2017 | Type 2 diabetes (T2D) and osteoporosis often coexist in patients, but managing both conditions can be a challenge. A comprehensive review published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism highlights…

Endocrine Society Lauds Novo Nordisk for Commitment to Affordable Insulin
May 10, 2017 | The Endocrine Society applauded Novo Nordisk's recent partnership with CVS Caremark on their new program Reduced Rx, a prescription savings program that offers discounts on certain medications…

Urine Metabolites May Help Predict Which Obese Teens Will Develop Diabetes
April 4, 2017 | Researchers have discovered a unique metabolic “signature” in the urine of diabetic, obese black teenagers that they say may become a way to predict the development of type 2 diabetes…

Children at High Risk of Diabetes Should be Screened by HbA1C and Oral Glucose Tolerance Tests
April 4, 2017 | Doctors should add an oral glucose tolerance test (OGTT) to their hemoglobin A1C (HbA1C) when they screen high-risk children for prediabetes and diabetes, new research…

Diabetes Control is More Difficult for Night Shift Workers
April 3, 2017 | People with type 2 diabetes have poorer control over their blood glucose levels when they work the night shift compared with those who work in the daytime…

In the US Military, White Kids and Officers' Kids More Likely to Use Diabetes Control Technology
April 3, 2017 | Even with equal access to healthcare in the United States military, significant disparities in caring for children with type 1 diabetes still exist…

Artificial Pancreas Improves Blood Sugar Control in Young Kids
April 3, 2017 | An artificial pancreas, which delivers insulin in an automated way to individuals with type 1 diabetes, appears to be safe and effective for use in children ages 5 to 8…

Program Equips Rural Primary Care Providers to Manage Complex Diabetes
April 3, 2017 | Primary care providers (PCPs) and community health workers in rural areas of New Mexico gained confidence in in their ability to manage patients with complex diabetes…

New Simple Tool Can Help Identify People at High Risk for Prediabetes
April 3, 2017 | The time to maximal sugar level during an oral glucose tolerance test is associated with higher risk for prediabetes and could give important information about…

Explore highlights of current education across the Endocrine Society.


How to Assess Second-Line Diabetes Agents for Patients at Risk for Major Osteoporotic Fractures
CME Activity | 0.5 AMA PRA Category 1 Credits™
Author: Doron Schneider, MD, FACP; Ann Schwartz, PhD, MPH
What are the best ways to help prevent your type 2 diabetes patient from avoiding major osteoporotic fractures? This interactive case study features can exploration of current science, clinical recommendations and medication options. The case study provides insights into mitigating fracture risk while effectively treating type 2 diabetes.

New Drugs in Diabetes – the Great Debate: How to Treat Type 2 Diabetes?
ENDO Session | No credit available
Faculty: David Nathan, MD and Daniel Drucker, MD
One of the most talked about sessions at ENDO 2017 was this much-anticipated debate. David Nathan, MD asks Are We Benefitting Anyone Other Than Pharma? while Daniel Drucker, MD sees True Innovation with Real Patient Benefits…

Can We Improve Cardiovascular Risk in Type 2 Diabetes?
ENDO Session | No credit available
Faculty: Cecilia C. Low Wang MD; Matthew Cavender, MD, MPH; Jennifer Green, MD; and William T. Cefalu, MD
Hear the latest about underlying mechanisms of cardiovascular disease and the impact of diabetes therapies in patients with diabetes.

Type 2 Diabetes Management in Patients with Cardiovascular Disease Risk
Beta Cells in Diabetes Case Study | 0.5 AMA PRA Category 1 Credit™
Faculty: Doron Schneider, MD and Bernard Zinman, MD
Follow this case study about Roberta, a 62-year-old African American secretary with type 2 diabetes, and hear insights on options to reduce cardiovascular risk.

Diabetes Diagnosis & Management 2017
Workshop Webcast | 7.5 AMA PRA Category 1 Credit™ and ABIM MOC Part 2 points
Planning Chairs: Johns (Jack) L. Leahy, MD and Carol H. Wysham, MD
Expert faculty provide state-of-the-art updates on cardiometabolic co-morbidities, new treatment options, and day-to-day strategies to manage patients with diabetes.

Best Practices for Type 2 Diabetes Management
Webcast | 1.0 AMA PRA Category 1 Credit™
Vivian A. Fonseca, MD, FRCP
Learn the best practices for the management of type 2 diabetes based on the latest guidelines and emerging treatment approaches.

New Options and Combinations in Diabetes Management: Optimizing Control and Individualizing Treatment
ENDO Satellite Symposium | 2.0 AMA PRA Category 1 Credits™
Chair: Anne L. Peters, MD
Faculty: Carol H. Wysham, MD; David M. Kayne, MD; and Janet B. McGill, MD
Use new options in GLP-1 receptor agonists, basal insulins, and combinations therein to improve patient outcomes.

Trial Updates in Type 2 Diabetes
CEU Satellite Symposium | 1.0 AMA PRA Category 1 Credit™
Carol H. Wysham, MD
Summarize cardiovascular complications and risk factors and integrate updated knowledge into practice, including the latest from the EMPA-REG and LEADER trials.

Diabetes @Point of Care
Practice Resource | Credit available
Find practical information when you need it the most to recognize signs, interpret results, and guide treatment decisions.

Epigenetic Changes in Patients with Type 2 Diabetes and Impact on Insulin Secretion and Action
ENDO Session | No credit available
Charlotte Ling, PhD
Learn about recent discoveries in potential epigenetic contributions to the development and progression of type 2 diabetes.

Transitions of Care: Type 1 Diabetes
Practice Resource | No credit available
Find resources for you and your patients to facilitate the challenging transition from pediatric to adult endocrine practice.

Explore highlights of current publications across the Endocrine Society journals. Visit academic.oup.com/endocrinesociety for more.


Systematic Characterization of Autophagy in Gestational Diabetes Mellitus
Endocrinology | August 1, 2017
Lulu Ji, Zhiguo Chen, Yating Xu, Guoping Xiong, Rui Liu, Chao Wu, Hanyang Hu, and Lin Wang
Gestational diabetes mellitus (GDM) is a metabolic disease characterized by impaired glucose intolerance beginning, or first diagnosed, during pregnancy . According to the population studies, GDM can affect 3% to 30% of pregnant women. In addition, women with a pregnancy complicated…

Temperature as a Circadian Marker in Older Human Subjects: Relationship to Metabolic Syndrome and Diabetes
JES | June 2, 2017
Brianna D. Harfmann, Elizabeth A. Schroder, Jonathan H. England, Natalie J. Senn, Philip M. Westgate, Karyn A. Esser, and Philip A. Kern
Circadian rhythms, or the 24-hour oscillations in physiological and behavioral processes, are essential to health. These rhythms are generated by a molecular clock present in every cell of…

Variation in Maturity-Onset Diabetes of the Young Genes Influence Response to Interventions for Diabetes Prevention
JCEM | April 27, 2017
Liana K Billings, Kathleen A Jablonski, A Sofia Warner, Yu-Chien Cheng, Jarred B McAteer, Laura Tipton, Alan R Shuldiner, David A Ehrmann, Alisa K Manning, Dana Dabelea, Paul W Franks, Steven E Kahn, Toni I Pollin, William C Knowler, David Altshuler, and Jose C Florez for the Diabetes Prevention Program Research Group
Maturity-onset diabetes of the young (MODY) is characterized by a nonketotic form of diabetes mellitus transmitted by an autosomal dominant mode of inheritance that is usually diagnosed before the age of 25 years…

Body Mass Index and Incident Type 1 and Type 2 Diabetes in Children and Young Adults: A Retrospective Cohort Study
JES | April 25, 2017
Ali Abbasi, Dorota Juszczyk, Cornelia H. M. van Jaarsveld, and Martin C. Gulliford
Obesity is a global health epidemic that is shifting toward children and young adults. More than one-half of adults, aged ≥18 years, were obese or overweight in 2014…

Costorage of Enteroendocrine Hormones Evaluated at the Cell and Subcellular Levels in Male Mice
Endocrinology | April 18, 2017
Linda J. Fothergill, Brid Callaghan, Billie Hunne, David M. Bravo, and John B. Furness
Recent studies of coexpression of gene transcripts and their products indicate that enteroendocrine cells (EECs) exhibit complex patterns of colocalization of hormones that contradict traditional…

Central Nervous System GLP-1 Receptors Regulate Islet Hormone Secretion and Glucose Homeostasis in Male Rats
Endocrinology | April 18, 2017
Lene Jessen, Eric P. Smith, Yvonne Ulrich-Lai, James P. Herman, Randy J. Seeley, Darleen Sandoval, and David D'Alessio
The brain-gut factor glucagon-like peptide 1 (GLP-1) plays a central role in normal glucose homeostasis. GLP-1 is released into the circulation from enteroendocrine l-cells scattered throughout…

Biliary Anomalies in Patients With HNF1B Diabetes
JCEM | March 17, 2017
Jarno L. T. Kettunen, Helka Parviainen, Päivi J. Miettinen, Martti Färkkilä, Marjo Tamminen, Pia Salonen, Eila Lantto, and Tiinamaija Tuomi
The clinical spectrum of organogenetic anomalies associated with HNF1B mutations is heterogeneous. Besides cystic kidney disease, diabetes, and various other manifestations, odd cases…

Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial
JCEM | March 15, 2017
Natalia McInnes, Ada Smith, Rose Otto, Jeffrey Vandermey, Zubin Punthakee, Diana Sherifali, Kumar Balasubramanian, Stephanie Hall, and Hertzel C. Gerstein
Type 2 diabetes is typically treated using lifestyle approaches and a stepwise addition of oral and injectable medications…

Menopausal Hormone Therapy and Type 2 Diabetes Prevention: Evidence, Mechanisms, and Clinical Implications
Endocrine Reviews | March 8, 2017
Franck Mauvais-Jarvis, JoAnn E. Manson, John C. Stevenson, and Vivian A. Fonseca
Type 2 diabetes has reached epidemic proportions in the United States. Large, randomized controlled trials suggest that menopausal hormone therapy (MHT) delays the onset of type 2 diabetes in women…

Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice
Endocrinology | March 8, 2017
Aaron R. Cox, Carol J. Lam, Matthew M. Rankin, Jacqueline S. Rios, Julia Chavez, Claire W. Bonnyman, Kourtney B. King, Roger A. Wells, Deepti Anthony, Justin X. Tu, Jenny J. Kim, Changhong Li, and Jake A. Kushner
The impact of incretins upon pancreatic β-cell expansion remains extremely controversial. Multiple studies indicate that incretin-based therapies can increase…

For a complete list of Endocrine Society guidelines, visit endocrine.org/guidelines.


Diabetes Technology—Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults
JCEM | September 2, 2016
Anne L. Peters(chair), Andrew J. Ahmann, Tadej Battelino, Alison Evert, Irl B. Hirsch, M. Hassan Murad, William E. Winter, and Howard Wolpert
Continuous subcutaneous insulin infusion and continuous glucose monitoring have an important role in the treatment of diabetes. Data from randomized controlled trials are limited on the use of…

Diabetes and Pregnancy
JCEM | December 4, 2013
Ian Blumer, Eran Hadar, David R. Hadden, Lois Jovanovič, Jorge H. Mestman, M. Hassan Murad, and Yariv Yogev
Using an evidence-based approach, this Diabetes and Pregnancy Clinical Practice Guideline addresses important clinical issues in the contemporary management of women with type 1 or type 2 diabetes…

Management of Hyperglycemia in Hospitalized Patients in Non-critical Care Setting
JCEM | July 2, 2013
Guillermo E. Umpierrez, Richard Hellman, Mary T. Korytkowski, Mikhail Kosiborod, Gregory A. Maynard, Victor M. Montori, Jane J. Seley, and Greet Van den Berghe
Hyperglycemia is a common, serious, and costly health care problem in hospitalized patients. Observational and randomized controlled studies indicate that improvement in glycemic control results…

Evaluation and Management of Adult Hypoglycemic Disorders
JCEM | April 30, 2011
Philip E. Cryer, Lloyd Axelrod, Ashley B. Grossman, Simon R. Heller, Victor M. Montori, Elizabeth R. Seaquist, and F. John Service
We recommend evaluation and management of hypoglycemia only in patients in whom Whipple's triad--symptoms, signs, or both consistent with hypoglycemia, a low plasma glucose concentration, and…

Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk
JCEM | January 14, 2009
James L. Rosenzweig, Ele Ferrannini, Scott M. Grundy, Steven M. Haffner, Robert J. Heine, Edward S. Horton, and Ryuzo Kawamori
Healthcare providers should incorporate into their practice concrete measures to reduce the risk of developing CVD and T2DM. These include the regular screening and identification of patients at…

For additional meetings, visit the Endocrine Society’s Worldwide Endocrinology Calendar at endocrine.org/calendar.


6th Annual Diabetes Symposium
Dates: October 6, 2017
Location: Philadelphia, Pennsylvania
Sponsor: Sidney Kimmel Medical College at Thomas Jefferson University

Keystone Symposium on Organ Crosstalk in Obesity and NAFLD
Dates: January 21–25, 2018
Location: Keystone, Colorado
Sponsor: Keystone Symposia on Molecular and Cellular Biology

54th Annual Clinical Diabetes and Endocrinology Conference
Dates: January 20–23, 2018
Location: Snowmass Village, Colorado
Sponsor: National Jewish Health in collaboration with the Clinical Diabetes Endocrine Institute

Keystone Symposium on Bioenergetics and Metabolic Disease
Dates: January 21–25, 2018
Location: Keystone, Colorado
Sponsor: Keystone Symposia on Molecular and Cellular Biology

Keystone Symposium on Frontiers in Islet Biology and Diabetes
Dates: February 4–8, 2018
Location: Keystone, Colorado, United States
Sponsor: Keystone Symposia on Molecular and Cellular Biology

ENDO 2018
Dates: March 17–20, 2018
Location: Chicago, Illinois, United States
Sponsor: Endocrine Society
ENDO is the world’s largest event for presenting and obtaining the latest in endocrine science and medicine with an extensive program covering a broad array of topics, various networking opportunities, poster sessions, updates on new products and technologies at the ENDOExpo, and more.

Resources